FDA approves New Therapy Aimed at a New Target in Esophageal Cancer at the GE Junction
FDA approves Zolbetuximab (Vyloy) as a first‑line treatment for patients with advanced HER2‑negative Esophageal Cancer found at the junction of the stomach and the esophagus (GE Junction) whose cancer overexpresses a protein called Claudin 18.2.
FDA approves Zolbetuximab (Vyloy) as a first‑line treatment for advanced HER2‑negative esophageal adenocarcinoma at the gastro‑esophageal junction that overexpresses Claudin 18.2, based on two phase‑III trials (SPOTLIGHT and GLOW) demonstrating a 25 % reduction in risk of death versus chemotherapy alone.
This approval provides a new targeted therapeutic option for a subset of esophageal cancer patients who have limited effective treatments and poor survival rates.
Bizonyítékszint: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Kapcsolódó jelek
- Advances in targeted therapy for esophageal cancer
- A review of esophageal cancer research: emerging trends, progress and perspectives
- An esophageal cancer clinical trial - ES3
- Case Report: Small bowel metastasis from esophageal squamous cell carcinoma: a case series and systematic review of clinical characteristics, tropism, and survival outcomes
- Current landscape of immunotherapy in esophageal cancer: a literature review